ClinicalTrials.gg
CompletedNCT01281527PALMFlexSUpdated Mar 10, 2014

Paliperidone Palmitate Flexible Dosing in Schizophrenia

A Phase 3 interventional study of Paliperidone Palmitate in Schizophrenia, sponsored by Janssen-Cilag International NV. Completed at 129 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-10.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,044
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
5th of 115
1,044 · median 178
Started
2010
with 7 others
Phase 3
41 of 115
none open now
Registered
61st of 115
by date
Lead sponsor
6 of 115
Janssen-Cilag International NV

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 5th largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 61st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.

Read the detailed description

This study explores the tolerability, safety and treatment response of flexibly dosed paliperidone palmitate in approximately 1,000 patients with schizophrenia previously unsuccessfully treated with an oral or LAI antipsychotic medication. Non-acute and acute patients will be involved in the study. This study consists of a screening phase, a 6-month core treatment phase, and an optional extension phase. A transition period of preferably a maximum of 4 weeks will be allowed for the previous oral antipsychotic. When switching patients from previous LAI antipsychotics, paliperidone palmitate will be initiated in place of the next scheduled injection. Patients without source documentation of previous risperidone or paliperidone exposure must undergo oral tolerability testing with paliperidone ER (3 mg/day) for the 2 days prior to Baseline Visit. Patients who successfully complete the 6-month core treatment phase and would like to continue treatment with paliperidone palmitate may be enrolled in an optional extension phase until paliperidone palmitate is available in their respective country or until a maximum duration of 12 months after the last subject has completed the 6-month core treatment phase, whichever comes first. Patients will receive, without cost, paliperidone palmitate. Patients entering this optional extension phase, will receive once monthly injections with paliperidone palmitate. The recommended maintenance dose for these monthly injections is 75 mg eq. once monthly but flexible dosing in the range of 50 to 150 mg eq. once monthly will be allowed. The doctor may flexibly increase or decrease the dose preferably by one dosing level (within the range of 50 to 150 mg eq.) according to patients' clinical needs. During the extension phase, two types of visits can be distinguished: 'assessment visits' and 'treatment-only visits'. At each assessment visit (once every 3 months +/- 7 days), patients will receive their injection and will be questioned about adverse events (AEs). Body weight will also be assessed. Paliperidone palmitate will be given once monthly by injection in either the upper arm or buttocks muscle, but start every time with upper arm application. The recommended maintenance dose for these monthly injections is 75 mg eq., range could be between 50 to 150 mg eq.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Paliperidone palmitate
  • Schizophrenia
  • Intramuscular injection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Meet the criteria for schizophrenia Currently non-acute, i.e., on the same antipsychotic medication used for the treatment of schizophrenia given in an adequate dose and a CGI-S change \<= 1 in the past 4 weeks before enrollment Patient has been given an adequate dose of either an appropriate oral antipsychotic, or a protocol-defined LAI antipsychotic for an adequate period of time prior to enrollment, but current treatment is considered unsuccessful OR Patients with acute symptoms of schizophrenia, previously treated with an oral antipsychotic, having a baseline total Positive and Negative Syndrome Scale (PANSS) score >= 80 and a baseline CGI-S score >= 4 Women must be for at least 1 year, surgically sterile, abstinent (at the discretion of the investigator/per local regulations), or if sexually active, be practicing a highly effective method of as local regulations permit, and before entry, must agree to continue to use the same method of contraception throughout the study Is cooperative and reliable, and agrees to receive regular injections and complete all aspects of the protocol Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

The patient's psychiatric diagnosis is due to direct pharmacological effects of a substance (e.g., a drug of abuse or medication) or a general medical condition (e.g., clinically notable hypothyroidism) First antipsychotic treatment ever, i.e., patient has never been treated with antipsychotics before and antipsychotic treatment given in this study will be the first antipsychotic treatment that the patient will have ever received On clozapine during the last 3 months Patients who remain at imminent risk of suicide even after clinical intervention Serious unstable medical condition, including recent and present laboratory abnormalities

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,044 participants (actual)

Study arms

  • Experimental
    Paliperidone Palmitate

    Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)

    Drug: Paliperidone Palmitate

Interventions

06

What researchers measure

Primary outcomes

  1. Improved efficacy for non-acute patients transitioned due to lack of efficacy, as measured by the total PANSS score at endpoint versus baseline.

    Time frame: Baseline to 6 months or early discontinuation

  2. Improved efficacy for acute patients, as measured by the total PANSS score at endpoint versus baseline.

    Time frame: Baseline to 6 months or early discontinuation

  3. Maintained efficacy for non-acute patients transitioned for other reasons based on PANSS score at endpoint versus baseline.

    Time frame: Baseline to 6 months or early discontinuation

Secondary outcomes

  1. Change from baseline in Clinical Global Impression-Severity Scale [CGI-S]

    Time frame: Baseline, week 1, month 1, 2, 3 and 6

  2. Change from baseline in personal and social functioning (Personal and Social Performance Scale [PSP])

    Time frame: Baseline, week 1, month 1, 2, 3 and 6

  3. Change from baseline in Health status (Self-reported health status questionnaire [SF-36])

    Time frame: Baseline, month 3 and 6

  4. Change from baseline in Measure of Health Outcome (EQ-5D)

    Time frame: Baseline, month 3 and 6

  5. Change from baseline in Patient well-being (Subjective Well-Being under Neuroleptics Scale [SWN-S]);

    Time frame: Baseline, month 3 and 6

07

Study locations

129 sites
  • Salzburg N/A, Austria
  • Brussel, Belgium
  • Dave, Belgium
  • Diest, Belgium
  • Kruishoutem, Belgium
  • Liege, Belgium
  • Melle, Belgium
  • Roeselare, Belgium
  • Sint-Denijs-Westrem, Belgium
  • Tournai, Belgium
  • Rijeka, Croatia
  • Zagreb, Croatia
  • Aalborg, Denmark
  • København V, Denmark
  • Randers, Denmark
  • Tallinn, Estonia
  • Bar Le Duc, France
  • Bron, France
  • Clermont Ferrand, France
  • Dax, France
  • Dijon Cedex, France
  • Dole, France
  • Lille, France
  • Limoges Cedex 1, France
  • Montpellier, France
  • Nimes, France
  • Paris, France
  • Saint Nazaire, France
  • St Priest En Jarez, France
  • Strasbourg Cedex, France
  • Villejuif Cedex, France
  • Bad Saarow, Germany
  • Berlin, Germany
  • Bielefeld, Germany
  • Bochum, Germany
  • Butzbach, Germany
  • Dresden, Germany
  • Gelsenkirchen, Germany
  • Greifswald, Germany
  • Hamburg, Germany
  • Heidelberg, Germany
  • Königsbrück, Germany
  • Mittweida, Germany
  • Oranienburg, Germany
  • Regensburg, Germany
  • Stralsund, Germany
  • Ulm, Germany
  • Westerstede, Germany
  • Würzburg, Germany
  • Arta, Greece
  • Athens, Greece
  • Katerini, Greece
  • Thessalonikis, Greece
  • Thessaloniki, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pécs, Hungary
  • Pardesia, Israel
  • Ramat Gan, Israel
  • Tirat Hacarmel, Israel
  • Daugavpils, Latvia
  • Jelgava, Latvia
  • Liepaja, Latvia
  • Riga, Latvia
  • Sigulda, Latvia
  • Strenci, Latvia
  • Panevezys, Lithuania
  • Vilnius, Lithuania
  • Groningen, Netherlands
  • Almada N/A, Portugal
  • Angra Do Heroísmo, Portugal
  • Castelo Viegas N/A, Portugal
  • Coimbra, Portugal
  • Lisboa, Portugal
  • Porto, Portugal
  • Alcorcon, Spain
  • Alicante, Spain
  • Barcelona, Spain
  • Burgos, Spain
  • Coslada, Spain
  • Elche, Spain
  • Madrid, Spain
  • Malaga N/A, Spain
  • Palma De Mallorca, Spain
  • San Juan De Alicante, Spain
  • Sant Boi De Llobregat, Spain
  • Santa Coloma De Gramenet, Spain
  • Vigo, Spain
  • Zamora, Spain
  • Zaragoza, Spain
  • Göteborg, Sweden
  • Lidingö, Sweden
  • Malmö, Sweden
  • Mölndal, Sweden
  • Spånga, Sweden
  • Upplands-Väsby, Sweden
  • Solothurn, Switzerland
  • Zürich, Switzerland
  • Ankara N/A, Turkey
  • Ankara, Turkey

Showing the first 100 of 129 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Schreiner A, Bergmans P, Cherubin P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Hargarter L. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther. 2014 Oct 1;36(10):1372-88.e1. doi: 10.1016/j.clinthera.2014.08.014. Epub 2014 Oct 23. Erratum In: Clin Ther. 2014 Nov 1;36(11):1705. PubMed 25444566 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2012 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2011
First posted
Jan 24, 2011
Start
Nov 2010
Primary completionActual
Nov 2012
CompletionActual
Nov 2013
Last update
Mar 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01281527
Responsible party
Sponsor
First posted
Jan 24, 2011
Start date
Nov 2010
Primary completion
Nov 2012
Completion
Nov 2013
Last update
Mar 10, 2014

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion